836 INDEX
hyaluronidase, 144
Hydreaseehydroxyurea
hydrocortisone, 472, 779
hydrogen peroxide, 151
hydropic degeneration, 40
hydroxyurea, 780
hydroxyzine, 780
for atopic disease, 181
for cutaneous mastocytosis, 623
for cutaneous mucinosis, 624
hygiene hypothesis, 175
hymenoptera stings, 240–241
clinical features, 243,262–264
diagnostics, 246
differential diagnosis, 245
treatment, 247
hyperadrenocorticism (HAC)
adrenal dependentseeadrenal dependent
hyperadrenocorticism
canine, 394–403
alopecia, 60,83,395,404, 406
clinical features, 395–396,404–408
course and prognosis, 403
diagnostics, 397–399
differential diagnosis, 396
signalment/history, 395
therapeutics, 400–402
treatment monitoring, 403
feline (skin fragility syndrome), 409–412
clinical features, 60,84,410,412–415
therapeutics, 411–412
iatrogenic, 394, 395,408,409,413–415
keratinization defects, 435, 455
pituitary dependentseepituitary dependent
hyperadrenocorticism
see alsoalopecia X
hyperandrogenism, 339, 350
hyperestrogenism, 339,348–349
alopecia, 60–61,88–89
hypergranulosis, 40
hyperkeratosis, 40
hyperlipidemia, 64,123, 613
hyperpigmentation, 13, 65–66
canine hyperadrenocorticism, 396, 407
postinflammatory, 65
hyperprogesteronemia, 339, 349
hypersensitivity reactionsseeallergic reactions
hyperthyroidism, feline
alopecia, 60,87–88
clinical features, 338, 343
hypoaminoacidemia, 665, 667
hypochloriteseebleach
hypogranulosis, 40
hypomelanosis, 40
hypophysectomy, 400
hypopigmentation, 13, 65–66, 67
hypopituitarism (pituitary dwarfism), 338, 344
alopecia, 60, 85
hypothyroidism with, 417, 423
hypothalamic-pituitary-adrenal (HPA) axis
abnormalities, 337
hypothyroidism, 416–422
clinical features, 60,86,418–419,423–428
congenital, 417
diagnostics, 419–421
differential diagnosis, 419
etiology/pathophysiology, 416–417
keratinization defects, 435, 455
signalment/history, 417
treatment, 421–422,428–429
hypotrichosis, feline hereditary, 61Ibizan hound, 459
ibuprofen, 780
ichthyosis, 62,99, 432
epidermolytic, 432, 442
nonepidermolytic, 432,440–441
IgE (immunoglobulin E), 174, 178, 482
IIS-PAA (incomplete iron salt of polyacrylic acid), 151
IL-31, 175
Imaverolseeenilconazole
imidacloprid, 302, 637
imipenem, 550, 780
imiquimod, 369, 715
immune-mediated diseases
claw and clawfold region, 66,133–134,590, 591
nasal planum, 67
panniculitis, 563
pigmentary abnormalities, 65
immunocompromised host
cryptococcosis, 521
dermatophytosis, 321
mycobacterial infections, 510, 511
nocardiosis, 535
immunohistochemistry
for epitheliotropic lymphoma, 369
for histiocytic proliferative disorders, 384, 385–386
for viral dermatoses, 715
immunosuppressive therapy
adverse effects, 197–198
for anal furunculosis/perianal fistula, 163–164
for atopic disease, 180–181
for autoimmune blistering diseases, 195–196, 197
for lupus erythematosus, 472
for uveodermatologic syndrome, 693–694
for vasculitis, 702
see alsoazathioprine; chlorambucil; corticosteroids;
cyclosporine; leflunomide; mycophenolate
mofetil
impetigo, 213, 214, 220,221–222
impression smears, 46,53–55
Imuranseeazathioprine
indolent ulcer (rodent ulcer), 351
clinical features,121,353, 361
diagnostics, 353, 354
signalment/history, 352
treatment, 355
infection, vs colonization, 212